- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02927665
A Prospective Multicenter Post Approval Study of the ReShape™ Integrated Dual Balloon System in Obese Subjects (ReShapePAS)
28. mars 2019 oppdatert av: ReShape Lifesciences
The ReShape Post Approval Study is a prospective multicenter study of the ReShape(TM) Integrated Dual Balloon System in Obese Subjects.
Studieoversikt
Detaljert beskrivelse
The ReShape Post Approval Study is a post-approval, multicenter, single arm, open label clinical study intended to collect valid scientific evidence regarding the safety and efficacy of the ReShape Dual Balloon as an adjunct to diet and exercise in the treatment of BMI 30-40 subjects with one or more obesity-related comorbid conditions in a commercial clinical setting.
Studietype
Observasjonsmessig
Registrering (Faktiske)
186
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Alabama
-
Dothan, Alabama, Forente stater, 36305
- Digestive Health Specialists Of The Southeast
-
-
Delaware
-
Newark, Delaware, Forente stater, 19713
- Christiana Institute of Advanced Surgery
-
-
Illinois
-
Barrington, Illinois, Forente stater, 60010
- Barrington Surgeons
-
-
Louisiana
-
Lafayette, Louisiana, Forente stater, 70503
- The Gastro Clinic
-
Metairie, Louisiana, Forente stater, 70001
- Surgical Specialist of Louisiana
-
-
Missouri
-
Saint Louis, Missouri, Forente stater, 63110
- Washington University
-
-
New Jersey
-
Teaneck, New Jersey, Forente stater, 07666
- North Jersey Laparoscopic Associates
-
-
New York
-
Roslyn Heights, New York, Forente stater, 11577
- New York Bariatric Group
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45241
- JourneyLite Physicians
-
Salem, Ohio, Forente stater, 44460
- Salem General Surgery
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater, 37909
- Gastrointestinal Associates, P.C.
-
Memphis, Tennessee, Forente stater, 38120
- MidSouth Bariatrics
-
-
Texas
-
San Antonio, Texas, Forente stater, 78240
- Sage Bariatric Institute
-
-
Washington
-
Shoreline, Washington, Forente stater, 98155
- Eviva
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
22 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Obese patients with a body mass index (BMI) of 30-40 and one or more obesity-related comorbid conditions, who have failed weight reduction with diet and exercise alone
Beskrivelse
Inclusion Criteria:
- Ages 22 and older
- Baseline BMI 30 - 40
- Failed weight reduction with diet and exercise alone
- One or more obesity-related comorbid conditions
- If female of child bearing potential, willing to avoid pregnancy during course of treatment
Exclusion Criteria:
- Prior gastrointestinal surgery with sequelae, i.e. obstruction, and/or adhesive peritonitis or known abdominal adhesions
- Prior open or laparoscopic bariatric surgery.
- Any inflammatory disease of the gastrointestinal tract including esophagitis, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease.
- Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresias or stenoses.
- A gastric mass.
- A hiatal hernia > 5 cm or ≤ 5 cm with associated severe or intractable gastro-esophageal reflux symptoms.
- A structural abnormality in the esophagus or pharynx such as a stricture or diverticulum that could impede passage of the delivery catheter and/or an endoscope.
- Achalasia or any other severe esophageal motility disorder that may pose a safety risk during the removal of the device
- Severe coagulopathy
- Hepatic insufficiency or cirrhosis
- Serious or uncontrolled psychiatric illness or disorder that could compromise patient understanding of or compliance with follow up visits and removal of the device after 6 months.
- Alcoholism or drug addiction.
- Patients unwilling to participate in an established medically-supervised diet and behavior modification program, with routine medical follow-up.
- Patients receiving daily prescribed treatment with aspirin, anti-inflammatory agents, anticoagulants or other gastric irritants.
- Patients who are unable or unwilling to take prescribed proton pump inhibitor medication for the duration of the device implant.
- Patients who are known to have, or suspected to have, an allergic reaction to materials contained in the system.
- Patients who have ever developed a serotonin syndrome and are currently taking any drug known to affect the levels of serotonin in the body [e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs)] should not undergo placement of the device.
- Patients who are pregnant or breast-feeding.
- Significant endoscopic abnormalities immediately prior to device insertion.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Study Subjects
Eligible subjects receiving ReShape Integrated Dual Balloon System treatment in a commercial clinical setting
|
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety of ReShape Dual Balloon Treatment
Tidsramme: 24 weeks
|
Safety of ReShape Dual Balloon Treatment using a composite endpoint consisting of all device- and/or procedure-related SAEs
|
24 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Studieleder: Scott Shikora, ReShape Lifesciences
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. september 2016
Primær fullføring (Forventet)
1. november 2019
Studiet fullført (Forventet)
1. desember 2019
Datoer for studieregistrering
Først innsendt
5. oktober 2016
Først innsendt som oppfylte QC-kriteriene
6. oktober 2016
Først lagt ut (Anslag)
7. oktober 2016
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
29. mars 2019
Siste oppdatering sendt inn som oppfylte QC-kriteriene
28. mars 2019
Sist bekreftet
1. mars 2019
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- ReShape Post Approval Study
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .